Increased immunogenicity and protective efficacy of a P. aeruginosa vaccine in mice using an alum and de-O-acylated lipooligosaccharide adjuvant system

JI Ryu, SR Wui, A Ko, HTT Do, YJ Lee… - … of microbiology and …, 2017 - koreascience.kr
Pseudomonas aeruginosa (P. aeruginosa) is an opportunistic pathogen that commonly
causes fatal infections in cystic fibrosis and burn patients as well as in patients who are …

Increased Immunogenicity and Protective Efficacy of a P. aeruginosa Vaccine in Mice Using an Alum and De-O-Acylated Lipooligosaccharide Adjuvant System

류지인, 위서리, 고아라, 이연정, 김학준… - Journal of Microbiology …, 2017 - dbpia.co.kr
Pseudomonas aeruginosa (P. aeruginosa) is an opportunistic pathogen that commonly
causes fatal infections in cystic fibrosis and burn patients as well as in patients who are …

[PDF][PDF] Increased Immunogenicity and Protective Efficacy of a P. aeruginosa Vaccine in Mice Using an Alum and De-O-Acylated Lipooligosaccharide Adjuvant System

JI Ryu, SR Wui, A Ko, HTT Do, YJ Lee… - J. Microbiol …, 2017 - scholar.archive.org
Pseudomonas aeruginosa (P. aeruginosa) is an opportunistic pathogen that commonly
causes fatal infections in cystic fibrosis and burn patients as well as in patients who are …

[HTML][HTML] Increased Immunogenicity and Protective Efficacy of a P. aeruginosa Vaccine in Mice Using an Alum and De-O-Acylated Lipooligosacc Adjuvant System

JI Ryu, SR Wui, A Ko, HTT Do, YJ Lee, HJ Kim, I Rhee… - 2017 - jmb.or.kr
Pseudomonas aeruginosa (P. aeruginosa) is an opportunistic pathogen that commonly
causes fatal infections in cystic fibrosis and burn patients as well as in patients who are …

Increased Immunogenicity and Protective Efficacy of a P. aeruginosa Vaccine in Mice Using an Alum and De-O-Acylated Lipooligosaccharide Adjuvant System

JI Ryu, SR Wui, A Ko, YJ Lee, H Do… - Journal of …, 2017 - pubmed.ncbi.nlm.nih.gov
Pseudomonas aeruginosa (P. aeruginosa) is an opportunistic pathogen that commonly
causes fatal infections in cystic fibrosis and burn patients as well as in patients who are …

Increased Immunogenicity and Protective Efficacy of a P. aeruginosa Vaccine in Mice Using an Alum and De-O-Acylated Lipooligosaccharide Adjuvant System.

JI Ryu, SR Wui, A Ko, YJ Lee, H Do, HJ Kim… - … of Microbiology and …, 2017 - europepmc.org
Pseudomonas aeruginosa (P. aeruginosa) is an opportunistic pathogen that commonly
causes fatal infections in cystic fibrosis and burn patients as well as in patients who are …

Increased Immunogenicity and Protective Efficacy of a P. aeruginosa Vaccine in Mice Using an Alum and De-O-Acylated Lipooligosaccharide Adjuvant System

JI Ryu, A Ko, YJ Lee, I Rhee, KS Kim… - Journal of Microbiology …, 2017 - papersearch.net
Pseudomonas aeruginosa (P. aeruginosa) is an opportunistic pathogen that commonly
causes fatal infections in cystic fibrosis and burn patients as well as in patients who are …

Increased Immunogenicity and Protective Efficacy of a P. aeruginosa Vaccine in Mice Using an Alum and De-O-Acylated Lipooligosaccharide Adjuvant System

JI Ryu, SR Wui, AR Ko, TT Do Hien… - Journal of …, 2017 - oldkmbase.medric.or.kr
Pseudomonas aeruginosa (P. aeruginosa) is an opportunistic pathogen that commonly
causes fatal infections in cystic fibrosis and burn patients as well as in patients who are …

Increased Immunogenicity and Protective Efficacy of a P. aeruginosa Vaccine in Mice Using an Alum and De-O-Acylated Lipooligosaccharide Adjuvant System

JI Ryu, A Ko, YJ Lee, I Rhee, KS Kim… - Journal of Microbiology …, 2017 - kiss.kstudy.com
Pseudomonas aeruginosa (P. aeruginosa) is an opportunistic pathogen that commonly
causes fatal infections in cystic fibrosis and burn patients as well as in patients who are …

Increased Immunogenicity and Protective Efficacy of a P. aeruginosa Vaccine in Mice Using an Alum and De-O-Acylated Lipooligosaccharide Adjuvant System

JI Ryu, SR Wui, A Ko, HTT Do, YJ Lee… - … of Microbiology and …, 2017 - agris.fao.org
Pseudomonas aeruginosa (P. aeruginosa) is an opportunistic pathogen that commonly
causes fatal infections in cystic fibrosis and burn patients as well as in patients who are …